Alison Lawton

Alison Lawton serves as the Chair of the Board of Directors at Dianthus Therapeutics, Inc. since September 2023 and is a current board member at BlueRock Therapeutics, X4 Pharmaceuticals, and ProQR Therapeutics NV. Lawton's past roles include Chair and board member at Magenta Therapeutics and president & CEO of Kaleido Biosciences. Additionally, Lawton holds a board position at Verastem and previously served on the board of Aeglea BioTherapeutics and Spyre Therapeutics. Lawton earned a BSc Hons in Pharmacology from King’s College London between 1981 and 1984.